Generic Name and Formulations:
Difenoxin HCl 1mg, atropine sulfate 0.025mg; tabs.
Bausch Health Companies Inc.
Indications for MOTOFEN:
Adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
Initially 2mg, then 1mg after each loose stool or 1mg every 3–4 hours as needed. Max 8mg/24hrs. Discontinue use if no improvement after 48hrs.
Diarrhea associated with organisms that penetrate the intestinal mucosa (eg, toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics. Children <2yrs old. Jaundice.
Monitor fluid and electrolyte balance. Withhold dose if severe dehydration or electrolyte imbalance occurs. Acute ulcerative colitis; discontinue if abdominal distention occurs or if other untoward symptoms develop. Advanced hepatorenal disease or abnormal liver function tests; hepatic coma may be precipitated. Children with Down's syndrome. Pregnancy (Cat.C). Nursing mothers: not recommended.
Opioid + anticholinergic.
Avoid in patients in whom anticholinergic drugs are contraindicated. Hypertensive crisis possible with concomitant MAOIs. May potentiate barbiturates, tranquilizers, narcotics, alcohol; monitor.
GI upset, dry mouth, epigastric distress, constipation, dizziness, drowsiness, headache, tiredness, nervousness, insomnia, confusion.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer